Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells

Recruiting

• Conditions: Graft Vs Host Disease

• Registration Number: NCT05167188
• Lead Sponsor: Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna

Brief Summary

Spontaneous, multicenter, prospective, non-pharmacological study. At the diagnosis of acute or chronic GvHD after HSCT, bone marrow cells will be analysed for MSC content and properties. Bone marrow aspirate will be performed according to usual clinical practise

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-14
• Study First Submitted: 2021-11-24
• Study First Submitted QC: 2021-12-07
• Study First Posted: 2021-12-22
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-23
• Last Update Posted: 2023-05-24
• Primary Completion: 2025-03
• Study Completion: 2025-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Patients (children and adults) developing acute or chronic GvHD after HSCT.
• Age 6 months- month-99 years,
• Landsky-Karnofsky> 70%,
• Acute or chronic GvHD needing further immunosuppressive treatment.

Exclusion Criteria

• Anything not included in the inclusion criteria.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of damage generated by acute or chronic GvHD on the MSCs after HSCT	Through study completion, an average of 1 year

Trial Locations

Locations (1)

AOU Città della Salute e della Scienza di Torino; 🇮🇹 Torino, Italy